Estatísticas Básicas
| LEI | 54930055TH0ZLSAQMJ38 |
| CIK | 1297184 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amphastar Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 1, 2026 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 7, 2026 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 7, 2026 |
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 - Net revenues of $171.2 million for the three months ended March 31, 2026 - GAAP net income of $6.4 million, or $0.14 per share, for the first quarter - Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter - Company to hold a conference call today at 2:00 |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP |
|
| April 13, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻Preliminary Proxy Statement ◻Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻Definitive Pr |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 12, 2026 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 3, 2026 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 6, 2026 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601( |
|
| March 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 3, 2026 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 6, 2026 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 3, 2026 (the “Effective Date”) between Amphastar Pharmaceuticals, Inc. (the “Company”), and (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). R E C I T A L S WHEREAS, the Company desires to continue to retain the services o |
|
| March 6, 2026 |
AMENDMENT TO CONTRACT RESEARCH AGREEMENT Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601( |
|
| February 26, 2026 |
AMPHASTAR PHARMACEUTICALS, INC. INSIDER TRADING POLICY (Adopted on June 2, 2025) Exhibit 19.1 AMPHASTAR PHARMACEUTICALS, INC. INSIDER TRADING POLICY (Adopted on June 2, 2025) A. POLICY OVERVIEW Amphastar Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company min |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 26, 2026 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 26, 2026 |
AMENDMENT 1 TO DISTRIBUTION AGREEMENT Exhibit 10.37 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601 |
|
| February 26, 2026 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Amphastar France Pharmaceuticals, S.A.S. France Amphastar UK Limited United |
|
| February 26, 2026 |
AMENDMENT 3 TO CONTRACT MANUFACTURING AGREEMENT Exhibit 10.36 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601 |
|
| February 26, 2026 |
Exhibit 10.35 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601 |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphasta |
|
| February 26, 2026 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025 - Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 - GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share, respectively, for the fourth quarter and fiscal year - |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): January 6, 2026 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 12, 2026 |
Exhibit 99.1 Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound Agreement expands Amphastar’s proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January, 12, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) today |
|
| November 6, 2025 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601( |
|
| November 6, 2025 |
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025 EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025 - Reports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025 - GAAP net income of $17.4 million, or $0.37 per share, for the third quarter - Adjusted non-GAAP net income of $44.7 million, or $0.93 per share, for the third quarter - Company to hold a conference ca |
|
| November 6, 2025 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601( |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 6, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 |
|
| November 6, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601( |
|
| October 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): October 21, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 1, 2025 |
144 0001611286 XXXXXXXX LIVE 0001297184 Amphastar Pharmaceuticals, Inc. 001-36509 11570 SIXTH STREET RANCHO CUCAMONGA CA 91730 909-980-9484 Petersen Floyd F. Director Common UBS Financial Services, Inc. 11 Madison Avenue 4th Floor New York NY 10010 500 13370.00 46495077 10/01/2025 NASDAQ Common 06/07/2022 RSU Issuer N 500 06/07/2022 N/A N Floyd Peterson c/o 11570 SIXTH STREET Rancho Cucamonga CA 9 |
|
| September 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): September 15, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 2, 2025 |
144 0001611286 XXXXXXXX LIVE 0001297184 Amphastar Pharmaceuticals, Inc. 001-36509 11570 SIXTH STREET RANCHO CUCAMONGA CA 91730 909-980-9484 Petersen Floyd F. Director Common UBS Financial Services, Inc. 11 Madison Avenue 4th Floor New York NY 10010 500 15450.00 46495077 09/02/2025 NASDAQ Common 06/07/2022 RSU Issuer N 500 06/07/2022 N/A N Floyd Peterson c/o 11570 SIXTH STREET Rancho Cucamonga CA 9 |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 8, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 12, 2025 |
Exhibit 99.1 Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA – August 12, 2025 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar”), a biopharmaceutical company focused o |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 7, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2025 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601( |
|
| August 7, 2025 |
Amended and Restated Certificate of Incorporation of Amphastar Pharmaceuticals, Inc, as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMPHASTAR PHARMACEUTICALS, INC. Amphastar Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: A. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on May 19, 2004. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH |
|
| August 7, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601( |
|
| August 7, 2025 |
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 - Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025 - GAAP net income of $31.0 million, or $0.64 per share, for the second quarter - Adjusted non-GAAP net income of $40.9 million, or $0.85 per share, for the second quarter - Company to hold a conference call today |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): July 18, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 4, 2025 |
Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF AMPHASTAR PHARMACEUTICALS, INC. (initially adopted on March 24, 2014) (as amended on February 23, 2023 and February 25, 2025) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES1 1.1REGISTERED OFFICE1 1.2OTHER OFFICES1 ARTICLE II - MEETINGS OF STOCKHOLDERS1 2.1PLACE OF MEETINGS1 2.2ANNUAL MEETING1 2.3SPECIAL MEETING1 2.4ADVANCE NOTICE PROCEDURES2 |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2025 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis |
|
| June 4, 2025 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMPHASTAR PHARMACEUTICALS, INC. Amphastar Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1.The name of the Corporation is Amphastar Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was |
|
| June 4, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMPHASTAR PHARMACEUTICALS, INC. Amphastar Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1.The name of the Corporation is Amphastar Pharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 7, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 7, 2025 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA – May 7, 2025 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2025. First Quarter Highlights ● Net |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻Preliminary Proxy Statement ◻Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻Definitive Pr |
|
| April 14, 2025 |
-i- AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CALIFORNIA 91730 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held at 11:30 a.m. Pacific Time on Monday, June 2, 2025 Dear Stockholders of Amphastar Pharmaceuticals, Inc.: Please be advised that the 2025 annual meeting of stockholders (the “Annual Meeting”) of Amphastar Pharmaceuticals, Inc., (or the “Company” or “Amphastar”) |
|
| April 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi |
|
| April 2, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ⌧ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defi |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphastar Pharmaceuticals, |
|
| March 3, 2025 |
Amphastar Pharmaceuticals, Inc. Insider Trading Policy, adopted on December 31, 2024 Exhibit 19.1 AMPHASTAR PHARMACEUTICALS, INC. INSIDER TRADING POLICY (Adopted on December 31, 2024) A. POLICY OVERVIEW Amphastar Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Compan |
|
| March 3, 2025 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Amphastar Medication Co., LLC California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Amphastar |
|
| February 27, 2025 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024 Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA – February 27, 2025 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended Decembe |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 27, 2025 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 |
|
| November 7, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K, BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. IN ADDITION, CERTAIN SCHEDULES (OR SIMILAR ATTACHMENTS) HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601( |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 6, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 6, 2024 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA – November 6, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2024. Third quarter |
|
| August 30, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 28, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 7, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2024 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024 Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024 RANCHO CUCAMONGA, CA – August 7, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2024. Second Quarter Highlights ● Net |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2024 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis |
|
| June 4, 2024 |
2015 Equity Incentive Plan of Amphastar Pharmaceuticals, Inc. (as amended and restated) Exhibit 10.1 AMPHASTAR PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN (As amended and restated by the Board on February 26, 2024, subject to, and contingent upon, stockholder approval at the 2024 annual meeting of the Company’s stockholders ) 1.Purposes of the Plan. The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ● |
|
| June 4, 2024 |
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program Exhibit 99.1 Amphastar Announces Additional $50 Million Increase to its Share Buyback Program RANCHO CUCAMONGA, Calif., June 4, 2024 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) today announced that on June 3, 2024, the Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expected to continue for an indefinite period of time. The prima |
|
| May 10, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Syndicated Loan Contract [Amphastar Nanjing Pharmaceuticals Inc.] (As the Borrower) [Nanjing Branch of Industrial and Commercial Bank of China Limited] (As the Lead Bank) [Na |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP |
|
| May 8, 2024 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA – May 8, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2024. First Quarter Highlights ● Net |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 8, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin |
|
| April 12, 2024 |
-i- AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CALIFORNIA 91730 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held at 11:00 a.m. Pacific Time on Monday, June 3, 2024 Dear Stockholders of Amphastar Pharmaceuticals, Inc.: Please be advised that the 2024 annual meeting of stockholders (the “Annual Meeting”) of Amphastar Pharmaceuticals, Inc., (or the “Company” or “Amphastar”) |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻Preliminary Proxy Statement ◻Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻Definitive Pr |
|
| April 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi |
|
| March 6, 2024 |
AMPH / Amphastar Pharmaceuticals, Inc. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) February 29, 2024 (Date of Event Which Requires Fili |
|
| February 29, 2024 |
Exhibit 10.33 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SEVENTH AMENDMENT TO SUPPLY AGREEMENT This seventh amendment ("Seventh Amendment") to the Supply Agreement by and between MannKind Corporation ("MannKind") and Amphastar Pha |
|
| February 29, 2024 |
Compensation Recovery Policy of the Company Exhibit 97.1 Amphastar Pharmaceuticals, Inc. COMPENSATION RECOVERY POLICY As adopted on August 4, 2023 Amphastar Pharmaceuticals, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Co |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Amphastar Pharmaceuticals, Inc. |
|
| February 29, 2024 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Amphastar Medication Co., LLC California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Amphastar |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphastar Pharmaceuticals, |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 28, 2024 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 28, 2024 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023 Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023 RANCHO CUCAMONGA, CA – February 28, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended Decembe |
|
| February 13, 2024 |
AMPH / Amphastar Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0281-amphastarpharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Amphastar Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate |
|
| February 9, 2024 |
AMPH / Amphastar Pharmaceuticals, Inc. / Zhang Jack Y. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 23, 2024 |
AMPH / Amphastar Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us03209r1032012324.txt us03209r1032012324.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) AMPHASTAR PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 03209R103 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| January 17, 2024 |
AMPH / Amphastar Pharmaceuticals, Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 amph1566-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) December 31, 2023 (Date |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 8, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 8, 2023 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023 Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 RANCHO CUCAMONGA, CA – November 8, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2023. Third Quarter |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): September 11, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 15, 2023 |
Exhibit 10.1 $300,000,000 2.00% Convertible Senior Notes due 2029 Amphastar Pharmaceuticals, Inc. PURCHASE AGREEMENT September 12, 2023 Jefferies LLC J.P. Morgan Securities LLC Wells Fargo Securities, LLC BofA Securities, Inc. As Representatives of the several Initial Purchasers c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York |
|
| September 15, 2023 |
Exhibit 99.1 Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes RANCHO CUCAMONGA, CA – September 11, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar”) today announced that it intends to offer, subject to market conditions and other factors, $300.0 million aggregate principal amount of convertible senior notes due 2029 (the |
|
| September 15, 2023 |
Exhibit 4.1 AMPHASTAR PHARMACEUTICALS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of September 15, 2023 2.00% Convertible Senior Notes due 2029 i TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions1 Section 1.02. References to Interest13 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.01. Designat |
|
| September 15, 2023 |
Exhibit 99.2 Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes RANCHO CUCAMONGA, CA – September 13, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar”) today announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 (the “notes”) in a private placement to persons reasonably belie |
|
| August 16, 2023 |
Exhibit 99.3 Amphastar Pharmaceuticals, Inc. Unaudited Pro Forma Condensed Combined Financial Statements (amounts in thousands) On June 30, 2023, Amphastar Pharmaceuticals, Inc., or the Company, completed its acquisition of BAQSIMI® glucagon nasal powder, or BAQSIMI®, or the Acquisition, pursuant to an asset purchase agreement, or the Purchase Agreement, with Eli Lilly & Company, or Lilly, dated A |
|
| August 16, 2023 |
Exhibit 99.1 Baqsimi® (glucagon) (A Product of Eli Lilly and Company) Abbreviated Financial Statements As of and for the Years Ended December 31, 2022 and 2021 (With Report of Independent Auditors) Index to Abbreviated Financial Statements Report of Independent Auditors3 Abbreviated Financial Statements Statements of Assets Acquired5 Statements of Revenues and Direct Expenses6 Notes to Abbrevia |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): June 30, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Inco |
|
| August 16, 2023 |
Exhibit 99.2 Baqsimi® (glucagon) (A Product of Eli Lilly and Company) Unaudited Abbreviated Financial Statements As of March 31, 2023 and December 31, 2022 and for the Three Months Ended March 31, 2023 and 2022 Index to Abbreviated Financial Statements (Unaudited) Abbreviated Financial Statements (Unaudited) Statements of Assets Acquired3 Statements of Revenues and Direct Expenses4 Notes to Abbr |
|
| August 9, 2023 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED MANUFACTURING SERVICES AGREEMENT BETWEEN ELI LILLY AND COMPANY AND AMPHASTAR PHARMACEUTICALS, INC. DATED AS OF June 30, 2023 TABLE OF CONTENTS Page Article 1 DEFINITIONS; INTE |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH |
|
| August 9, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ASSET PURCHASE AGREEMENT BY AND AMONG ELI LILLY AND COMPANY, AMPHASTAR MEDICATION CO., LLC, AND Amphastar Pharmaceuticals, Inc. DATED AS OF APRIL 21, 2023 TABLE OF CONTENTS Pa |
|
| August 9, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED TRANSITION SERVICES AGREEMENT BETWEEN ELI LILLY AND COMPANY AND AMPHASTAR PHARMACEUTICALS, INC. DATED AS OF June 30, 2023 TABLE OF CONTENTS Page Article I DEFINED TERMS1 Arti |
|
| August 9, 2023 |
Exhibit 10.4 CREDIT AGREEMENT dated as of June 30, 2023 among AMPHASTAR PHARMACEUTICALS, INC., as Borrower, The Subsidiaries of Borrower Party Hereto, as Guarantors, The Financial Institutions Party Hereto, as Lenders, and Wells Fargo Bank, National Association, as Administrative Agent, Swing Line Lender and L/C Issuer WELLS FARGO SECURITIES, LLC, CAPITAL ONE, NATIONAL ASSOCIATION, JPMORGAN CHASE |
|
| August 8, 2023 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023 Reports Net Revenues of $145.7 Million for the Three Months Ended June 30, 2023 RANCHO CUCAMONGA, CA – August 8, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2023. Second Quarter Highlights ● Net |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 8, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): June 30, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 30, 2023 |
Exhibit 99.1 Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly RANCHO CUCAMONGA, CA – June 30, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today announced that it has completed the previously announced acquisition of BAQSIMI® from Eli Lilly and Company (“Lilly”) (the “Acquisition”). Acquisition Highlights ● Provides Amphastar with a bran |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2023 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP |
|
| May 9, 2023 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023 Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023 RANCHO CUCAMONGA, CA – May 9, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2023. First Quarter Highlights ● Net |
|
| May 9, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT TO THE CONTRACT RESEARCH AGREEMENT 委托开发协议之修订协议 This Amendment to the Contract Research Agreement (this “Amendment”) is entered into by and between the following part |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 9, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 24, 2023 |
Exhibit 99.1 April 24, 2023 For Release:April 24, 2023 @ 6:45 a.m. ET Refer to:Jordan Bishop; [email protected]; 317-473-5712 (Lilly Media) Joe Fletcher; [email protected]; 317-296-2884 (Lilly Investors) Dan Dischner; [email protected]; 909-942-4153 (Amphastar Media) Bill Peters; [email protected]; 909-476-3416 (Amphastar Investors) Lilly to Divest BAQSIMI to Amphastar Lilly focused on |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 21, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy State |
|
| April 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ⌧ Defi |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻Preliminary Proxy Statement ◻Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻Definitive Pr |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 8, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 1, 2023 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Amphastar France Pharmaceuticals, S.A.S. France Amphastar UK Limited United |
|
| March 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Amphastar Pharmaceuticals, Inc. |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphastar Pharmaceuticals, |
|
| February 28, 2023 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022 Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022 RANCHO CUCAMONGA, CA – February 28, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended Decembe |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 28, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): February 23, 2023 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 24, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF AMPHASTAR PHARMACEUTICALS, INC. (initially adopted on March 24, 2014) (as amended on February 23, 2023) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES1 1.1REGISTERED OFFICE1 1.2OTHER OFFICES1 ARTICLE II - MEETINGS OF STOCKHOLDERS1 2.1PLACE OF MEETINGS1 2.2ANNUAL MEETING1 2.3SPECIAL MEETING1 2.4ADVANCE NOTICE PROCEDURES2 2.5NOTICE OF STOCKHOL |
|
| February 9, 2023 |
AMPH / Amphastar Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Amphastar Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 1, 2023 |
AMPH / Amphastar Pharmaceuticals Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Fili |
|
| January 27, 2023 |
AMPH / Amphastar Pharmaceuticals Inc / Zhang Jack Y. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 26, 2023 |
AMPH / Amphastar Pharmaceuticals Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us03209r1032012623.txt us03209r1032012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) AMPHASTAR PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 03209R103 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| January 20, 2023 |
AMPH / Amphastar Pharmaceuticals Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us03209r1032011923.txt us03209r1032011923.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) AMPHASTAR PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 03209R103 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 18, 2022 |
Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): November 15, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction o |
|
| November 18, 2022 |
Exhibit 10.1 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? SUPPLY AGREEMENT ? ???? ? This Supply Agreement (this ?Agreement?) is entered into by and between the following parties on November 15, 2022 (the ?Effective Date?): ?????? |
|
| November 8, 2022 |
Exhibit 10.1 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? CONTRACT RESEARCH AGREEMENT ?????? ? This Contract Research Agreement (this ?Agreement?) is entered into by and between the following parties on July 5, 2022 (the ?Effecti |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 7, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): November 7, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incor |
|
| November 7, 2022 |
EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022 ? Reports Net Revenues of $120.1 Million for the Three Months Ended September 30, 2022 ? RANCHO CUCAMONGA, CA ? November 7, 2022 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended September 30, 2022. ? Third |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 4, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of I |
|
| August 9, 2022 |
Exhibit 10.1 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? ? CONTRACT MANUFACTURING AGREEMENT ? ?????? ? This Contract Manufacturing Agreement (this ?Agreement?) is entered into by and between the following parties on April 19, 20 |
|
| August 8, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 8, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorpo |
|
| August 8, 2022 |
EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022 ? Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022 ? RANCHO CUCAMONGA, CA ? August 8, 2022 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended June 30, 2022. ? Second Quarter Highligh |
|
| July 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): July 5, 2022 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 10, 2022 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) ? ? ? ? ? ? ? ? ? ? Delaware 001-36509 33-0702205 (State or other jurisdiction of i |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): May 9, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporat |
|
| May 9, 2022 |
EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022 ? Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 ? RANCHO CUCAMONGA, CA ? May 9, 2022 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended March 31, 2022. ? First Quarter Highlight |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 19, 2022 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| April 14, 2022 |
DEFA14A 1 amph-20220414xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻Preliminary Proxy Statement ◻Confidential, for Use of the Commission Only (as p |
|
| March 11, 2022 |
Exhibit 21.1 ? SUBSIDIARIES OF THE COMPANY ? ? ? ? ? ? ? ? State of ? Country of ? ? Incorporation/ ? Incorporation/ Company Name Organization Organization International Medication Systems, Limited ? California ? United States of America Armstrong Pharmaceuticals, Inc. ? Massachusetts ? United States of America Amphastar Nanjing Pharmaceuticals, Inc. ? ? ? China Amphastar France Pharmaceuticals, S |
|
| March 11, 2022 |
Exhibit 107 ? Calculation of Filing Fee Tables ? Form S-8 (Form Type) ? Amphastar Pharmaceuticals, Inc. |
|
| March 11, 2022 |
As filed with the Securities and Exchange Commission on March 11, 2022 S-8 1 amph-20220311xs8.htm S-8 As filed with the Securities and Exchange Commission on March 11, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AMPHASTAR PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 33-0702205 (State or other jurisdiction of |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K ? ? ? ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended December 31, 2021 OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number 001-36509 ? |
|
| March 10, 2022 |
EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021 ? Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 ? RANCHO CUCAMONGA, CA ? March 10, 2022 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months and full-year ended Dece |
|
| March 10, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): March 10, 2022 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorpo |
|
| February 14, 2022 |
AMPH / Amphastar Pharmaceuticals Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fili |
|
| February 11, 2022 |
AMPH / Amphastar Pharmaceuticals Inc / Zhang Jack Y. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 9, 2022 |
AMPH / Amphastar Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0255-amphastarpharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Amphastar Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate |
|
| January 28, 2022 |
AMPH / Amphastar Pharmaceuticals Inc / BlackRock Inc. Passive Investment us03209r1032012822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) AMPHASTAR PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 03209R103 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 17, 2021 |
AMPHASTAR PHARMACEUTICALS, INC. 11570 6th Street, Rancho Cucamonga, CA 91730 ? Telephone: (909) 980-9484 ? Fax: (909) 481-6133 ? November 17, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Michael Davis Celeste Murphy ? Re: Amphastar Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed Novem |
|
| November 15, 2021 |
United States securities and exchange commission logo November 15, 2021 Jack Zhang Chief Executive Officer Amphastar Pharmaceuticals, Inc. |
|
| November 9, 2021 |
As filed with the Securities and Exchange Commission on November 9, 2021 ? ? ? ? As filed with the Securities and Exchange Commission on November 9, 2021 Registration No. |
|
| November 9, 2021 |
Exhibit 10.1 ? ? ? ? ? ? ? ? ? $140,000,000 CREDIT FACILITY ? ? ? CREDIT AGREEMENT ? ? Dated as of August 4, 2021 ? ? by and among ? AMPHASTAR PHARMACEUTICALS, INC., TOGETHER WITH THE OTHER PERSONS THAT ARE NOW OR FROM TIME TO TIME BECOME BORROWERS HEREUNDER, as Borrowers, ? THE OTHER PERSONS PARTY HERETO DESIGNATED FROM TIME TO TIME AS CREDIT PARTIES, ? CAPITAL ONE, NATIONAL ASSOCIATION, for itse |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 9, 2021 |
Exhibit 4.3 ? AMPHASTAR PHARMACEUTICALS, INC. INDENTURE Dated as of, 20 [] Trustee ? ? ? ? ? TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE?1 Section 1.1Definitions?1 Section 1.2Other Definitions?4 Section 1.3Incorporation by Reference of Trust Indenture Act?5 Section 1.4Rules of Construction?5 ARTICLE II THE SECURITIES?5 Section 2.1Issuable in Series?5 Section 2.2Esta |
|
| November 9, 2021 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? ? ? ? ? Share Purchase Agreement ?????? ? ? ? ? ? August 19, 2021 2021 8?19? ? ? Share Purchase Agreement ?????? This Share Purchase Agreement (this ?Agreement?) is executed |
|
| November 8, 2021 |
EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 ? Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021 ? RANCHO CUCAMONGA, CA ? November 8, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended September 30, 2021. ? Third |
|
| November 8, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): November 8, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incor |
|
| August 23, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 19, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 19, 2021 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 10, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 5, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of I |
|
| August 9, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 4, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of I |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2021 |
Exhibit 10.1 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ? SIXTH AMENDMENT TO SUPPLY AGREEMENT This sixth amendment (?Sixth Amendment?) to the Supply Agreement by and between MannKind Corporation (?MannKind?) and Amphastar Pharma |
|
| August 9, 2021 |
EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021 ? Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021 ? RANCHO CUCAMONGA, CA ? August 9, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended June 30, 2021. ? Second Quarter Highligh |
|
| August 9, 2021 |
Exhibit 10.3 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? Share Repurchase Agreement ?????? ? 2021?5?6? May 6, 2021 ? ? Share Repurchase Agreement ?????? This Share Repurchase Agreement (this ?Agreement?) is entered into on May 6 |
|
| August 9, 2021 |
Exhibit 10.2 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([***]), HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Share Purchase Agreement ?????? ? May 6, 2021 2021?5?6? ? ? Share Purchase Agreement ?????? This Share Purchase Agreement (this ?Agreement?) is executed on May 6, 2021 by th |
|
| August 9, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): August 9, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorpo |
|
| June 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 7, 2021 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) ? ? ? ? ? ? ? ? ? ? Delaware 001-36509 33-0702205 (State or other jurisdiction of in |
|
| May 7, 2021 |
Exhibit 99.1 Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary ? RANCHO CUCAMONGA, CA ? May 7, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (?ANP?). As part of the restructuring, Amphastar will buyback 26% of ANP?s equity current |
|
| May 7, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): May 6, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Inco |
|
| May 7, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy |
|
| May 7, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2021 |
EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021 ? Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021 ? RANCHO CUCAMONGA, CA ? May 6, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months ended March 31, 2021. ? First Quarter Highlight |
|
| May 6, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): May 6, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporat |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?Definitive Pr |
|
| April 14, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| March 15, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event Reported): March 15, 2021 ? Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorpo |
|
| March 15, 2021 |
Exhibit 21.1 ? SUBSIDIARIES OF THE COMPANY ? ? ? ? ? ? ? ? State of ? Country of ? ? Incorporation/ ? Incorporation/ Company Name Organization Organization International Medication Systems, Limited ? California ? United States of America Armstrong Pharmaceuticals, Inc. ? Massachusetts ? United States of America Amphastar Nanjing Pharmaceuticals, Inc. ? ? ? China Nanjing Letop Biological Technology |
|
| March 15, 2021 |
As filed with the Securities and Exchange Commission on March 15, 2021 Registration No. |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K ? ? ? ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended December 31, 2020 OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number 001-36509 ? |
|
| March 15, 2021 |
Exhibit 4.2 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? The following information describes our common stock and preferred stock, as well as certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This description is only a summary and does not purport to be complete. It is su |
|
| March 15, 2021 |
EXHIBIT 99.1 ? Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020 ? Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 ? RANCHO CUCAMONGA, CA ? March 15, 2021 ? Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (?Amphastar? or the ?Company?) today reported results for the three months and full-year ended Decem |
|
| March 15, 2021 |
Exhibit 10.40 ? ? ? EIGHTH MODIFICATION TO THE LOAN AGREEMENT ? Borrower: International Medication Systems, Limited ? Lender: East West Bank ? 11570 6th Street ? Loan Servicing Department ? Rancho Cucamonga, CA 91730 ? 9300 Flair Drive, 6th Floor ? ? ? ? ? El Monte, CA 91731 ? This EIGHTH MODIFICATION TO THE LOAN AGREEMENT is attached to and by this reference is made a part of the Business Loan Ag |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 12, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03209R103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filin |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Amphastar Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 26, 2021 |
us03209r1032012621.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) AMPHASTAR PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 03209R103 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 12, 2021 |
Exhibit 99.1 Investor Presentation January 2021 Exhibit 99.1 1 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact c |
|
| January 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): January 12, 2021 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 3, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 |
|
| November 6, 2020 |
Exhibit 10.1 PROMISSORY NOTE Borrower: International Medication Systems, Limited Lender: East West Bank 11570 6th Street Loan Servicing Department Rancho Cucamonga, CA 91730 9300 Flair Drive, 6th Floor El Monte, CA 91731 Principal Amount: $10,000,000.00 Date of Note: September 1, 2020 PROMISE TO PAY. INTERNATIONAL MEDICATION SYSTEMS, LIMITED ("Borrower") promises to pay to East West Bank ("Lender" |
|
| November 6, 2020 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020 Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020 RANCHO CUCAMONGA, CA – November 6, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2020. Third Quarter H |
|
| November 6, 2020 |
AMPHASTAR PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN Exhibit 99.1 AMPHASTAR PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN 1.Purposes of the Plan. The purposes of this Plan are: ●to attract and retain the best available personnel for positions of substantial responsibility, ●to provide additional incentive to Employees, Directors and Consultants, and ●to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock O |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 6, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 10, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2020 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Comm |
|
| August 10, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH |
|
| August 10, 2020 |
Exhibit 10.2 Loan No.: 2000017069-100 EIGHTH MODIFICATION AGREEMENT THIS EIGHTH MODIFICATION AGREEMENT (“Modification”) is dated as of this 15th day of June, 2020, by and among AMPHASTAR PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”) and ARMSTRONG PHARMACEUTICALS, INC., a Delaware corporation (“Guarantor”), on the one hand, and CATHAY BANK, a California banking corporation (“Lender”), |
|
| August 10, 2020 |
Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This Separation Agreement and General Release of Claims (“Agreement”) is freely entered into by Jason Shandell (“Shandell”), and Amphastar Pharmaceuticals, Inc. (the “Company”). (All of the parties are referred to herein collectively as the “parties”.) RECITALS Whereas, Shandell and the Company entered into that certain employment agr |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 6, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 6, 2020 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2020 Reports Net Revenues of $85.8 Million for the Three Months Ended June 30, 2020 RANCHO CUCAMONGA, CA – August 6, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2020. Second Quarter Highlights ● Net |
|
| June 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2020 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP |
|
| May 7, 2020 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2020 Reports Net Revenues of $84.7 Million for the Three Months Ended March 31, 2020 RANCHO CUCAMONGA, CA – May 7, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2020. First Quarter Highlights · Net r |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): May 7, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 15, 2020 |
AMPH / Amphastar Pharmaceuticals, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐Definitive Pr |
|
| April 15, 2020 |
AMPH / Amphastar Pharmaceuticals, Inc. DEF 14A - - DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defi |
|
| April 14, 2020 |
Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure Exhibit 99.1 Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure RANCHO CUCAMONGA, CA – April 13, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a California-based, specialty, generic pharmaceutical company, today announces a recent simplification of the Company’s management by removing a layer of management in the organizational |
|
| April 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 10, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Inc |
|
| April 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): April 13, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 13, 2020 |
Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure Exhibit 99.1 Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure RANCHO CUCAMONGA, CA – April 13, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a California-based, specialty, generic pharmaceutical company, today announces a recent simplification of the Company’s management by removing a layer of management in the organizational |
|
| March 16, 2020 |
Exhibit 10.39 AMPHASTAR PHARMACEUTICALS, INC. DEFERRED COMPENSATION PLAN Effective Date December 1, 2019 Amphastar Pharmaceuticals, Inc. Deferred Compensation Plan ARTICLE I Establishment and Purpose 1 ARTICLE II Definitions 1 ARTICLE III Eligibility and Participation 7 ARTICLE IV Deferrals 7 ARTICLE V Company Contributions 11 ARTICLE VI Payments from Accounts 12 ARTICLE VII Valuation of Account B |
|
| March 16, 2020 |
Exhibit 21.1 SUBSIDIARIES OF THE COMPANY State of Country of Incorporation/ Incorporation/ Company Name Organization Organization International Medication Systems, Limited California United States of America Armstrong Pharmaceuticals, Inc. Massachusetts United States of America Amphastar Nanjing Pharmaceuticals, Inc. China Nanjing Letop Fine Chemistry Co., Ltd. China Nanjing Hanxin Medical Technol |
|
| March 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36509 Amphastar Pharmaceuticals, |
|
| March 16, 2020 |
AMPH / Amphastar Pharmaceuticals, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on March 16, 2020 Registration No. |
|
| March 16, 2020 |
Description of Securities Registered Under Section 12 of the Exchange Act Exhibit 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following information describes our common stock and preferred stock, as well as certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This description is only a summary and does not purport to be complete. It is subj |
|
| March 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): March 12, 2020 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 12, 2020 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2019 Reports Net Revenues of $83.4 Million for the Three Months Ended December 31, 2019 RANCHO CUCAMONGA, CA – March 12, 2020 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31 |
|
| February 14, 2020 |
AMPH / Amphastar Pharmaceuticals, Inc. / Zhang Jack Y. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* AMPHASTAR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03209R 10 3 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 11, 2020 |
AMPH / Amphastar Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Amphastar Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 03209R103 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d- |
|
| February 4, 2020 |
AMPH / Amphastar Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment us03209r1032020320.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) AMPHASTAR PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 03209R103 - (CUSIP Number) December 31, 2019 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 8, 2019 |
AMPH / Amphastar Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 |
|
| November 7, 2019 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2019 Reports Net Revenues of $80.1 Million for the Three Months Ended September 30, 2019 RANCHO CUCAMONGA, CA – November 7, 2019 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2019. Third Quarter H |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): November 7, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 9, 2019 |
Exhibit 10.2 Certain identified information has been omitted from this document because it is not material and would be competitively harmful if publicly disclosed, and has been marked with “[***]” to indicate where omissions have been made. FIFTH AMENDMENT TO SUPPLY AGREEMENT This fifth amendment (“Fifth Amendment”) to the Supply Agreement by and between MannKind Corporation (“MannKind”) and Amph |
|
| August 9, 2019 |
AMPH / Amphastar Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPH |
|
| August 9, 2019 |
Exhibit 10.1 Loan No.: 3000029918-100 NINTH AMENDMENT TO LOAN AGREEMENT AND OTHER LOAN DOCUMENTS, AND SECOND EXTENSION AGREEMENT This Ninth Amendment to Loan Agreement and Other Loan Documents, and Second Extension Agreement (the “Amendment”) dated as of July 19, 2019 (“Reference Date”), which is effective as of June 22, 2019 (“Effective Date”), is between AMPHASTAR PHARMACEUTICALS, INC., a Delawa |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): August 7, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2019 |
EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2019 Reports Net Revenues of $79.0 Million for the Three Months Ended June 30, 2019 RANCHO CUCAMONGA, CA – August 7, 2019 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2019. Second Quarter Highlights · Net |
|
| June 19, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event Reported): June 19, 2019 Amphastar Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36509 33-0702205 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 19, 2019 |
Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz Exhibit 99.1 Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz RANCHO CUCAMONGA, CA – June 19, 2019 – Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) today announced that it has entered into a settlement agreement (the “Settlement Agreement”) with Momenta Pharmaceuticals Inc. and Sandoz Inc., (collectively, “Momenta/Sandoz”). Under the terms of the Settleme |
|
| June 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2019 Amphastar Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36509 33-0702205 (State or other jurisdiction of incorporation) (Commi |
|
| May 10, 2019 |
AMPH / Amphastar Pharmaceuticals, Inc. 10-Q Quarterly Report 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMP |
|
| May 10, 2019 |
Exhibit 10.1 CORPORATE RESOLUTION TO GRANT COLLATERAL / GUARANTEE Borrower: International Medication Systems, Limited Lender: East West Bank 11570 6th Street Loan Servicing Department Rancho Cucamonga, CA 91730 9300 Flair Drive, 6th Floor El Monte, CA 91731 Corporation: Amphastar Pharmaceuticals, Inc. 11570 6th Street Rancho Cucamonga, CA 91730 I, THE UNDERSIGNED, DO HEREBY CERTIFY THAT: THE CORPO |
